Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

Tumour lysis syndrome (TLS) represents a group of fatal metabolic derangements resulting from the rapid breakdown of tumour cells. TLS typically occurs soon after the administration of chemotherapy in haematologic malignancies but is rarely observed in solid tumours. Here, we report a case of brigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yadong, Wang, Tiange, Xue, Jianchao, Jia, Ziqi, Liu, Xinyu, Li, Bowen, Li, Ji, Li, Xiaoguang, Wang, Weiwei, Bing, Zhongxing, Cao, Lei, Cao, Zhili, Liang, Naixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721166/
https://www.ncbi.nlm.nih.gov/pubmed/34987411
http://dx.doi.org/10.3389/fphar.2021.809467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721166/
https://www.ncbi.nlm.nih.gov/pubmed/34987411
http://dx.doi.org/10.3389/fphar.2021.809467

Ejemplares similares